Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RMC 5552

Next Previous
Search
Drug Profile

RMC 5552

Alternative Names: RMC-5552

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REVOLUTION Medicines
  • Developer National Cancer Institute (USA); REVOLUTION Medicines; University of California
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Glioblastoma
  • No development reported Solid tumours

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 23 Apr 2025 Revolution Medicines in collaboration with University of California suspends phase-I clinical trials in Glioblastoma (Recurrent, Second-line therapy or greater) in USA due to interim analysis (IV) (NCT05557292)
  • 11 Oct 2023 Updated safety and adverse events data from a phase Ib/II trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top